- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02691871
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
February 22, 2016 updated by: Jie Wang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase I, Open-label, Dose-escalation Study of Apatinib in Combination With Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jie Wang, MD, PhD
- Phone Number: +86 13910704669
- Email: jiewang_hr@sina.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years to 65 years;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1;
- Life expectancy of more than 12 weeks;
- At least one measurable lesion according to RECIST 1.1 which has not received radiotherapy =< 3 months;
- Histologically/cytologically confirmed advanced/metastatic lung adenocarcinoma of stage IV with documented wild-type EGFR;
- Patients with one prior platinum-containing chemotherapy. In case of recurrent disease, one additional prior regimen is allowed for adjuvant and/or neoadjuvant therapy.
- Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥ 100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST ≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr ≤ 1×ULN, Cr clearance ≥ 50 mL/min, INR < 1.5 or PT < ULN+4s or APTT < 1.5×ULN, proteinuria < (++) or urinary protein ≤ 1.0 g/24 hrs;
- For women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug.
- Signed informed consent.
Exclusion Criteria:
- Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment;
- Other malignancy within the past five years other than basal cell skin cancer, or carcinoma in situ of the cervix;
- Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction);
- Major injuries and/or surgery =< 4 weeks prior to registration with incomplete wound healing. Patients who have received radiotherapy (except local palliative radiotherapy), chemotherapy, molecular targeted therapy =< 3 weeks, or nitrosoureas/mitomycin chemotherapy =< 6 weeks prior to registration;
- Patients with poor-controlled arterial hypertension (systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg) despite standard medical management;
- Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female ≥ 470 ms). Grade III-IV cardiac insufficiency according to NYHA criteria or echocardiography check: LVEF<50%;
- History of clinically significant haemoptysis =< 2 months (more than half of one tea spoon of fresh blood per day) prior to registration. Coagulation disfunction, hemorrhagic tendency or receiving anticoagulant therapy;
- History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood ≥ (++), and vasculitis) =< 3 months prior to randomization;
- Patients who have active brain metastases or leptomeningeal disease. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation ending at least 3 weeks prior to randomization, or after surgical resection performed at least 3 weeks prior to randomization. No evidence of Grade greater than or equal to 1 CNS hemorrhage based on pretreatment CT or MRI scan;
- Centrally located tumors of local invasion of major blood vessels, or distinct interstitial lung disease by the chest radiographic findings (CT or MRI);
- Treatment with other investigational drugs or other anti-cancer therapy;
- Previous therapy with other VEGFR inhibitors (other than bevacizumab);
- Previous therapy with docetaxel =< 6 months prior to registration;
- Treatment in another investigational trial =< 4 weeks prior to registration;
- Any contraindications for therapy with docetaxel. History of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80). History of hypersensitivity to apatinib and/or the excipients of the trial drugs;
- Active or chronic hepatitis C and/or B infection, or other active uncontrolled infection;
- History of immunodeficiency disease (including HIV positive), concurrent acquired or congenital immunodeficiency syndrome, or history of organ transplantation;
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =< 6 months prior to registration;
- History of arterial or venous thromboembolic events (e.g. CVA, DVT and pulmonary embolism) =< 12 months prior to randomization;
- Administration of strong/potent cytochrome P450 (CYP)3A4 inhibitors within 7 days, or inducers within 12 days;
- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study;
- History of mental diseases;
- Other conditions regimented at investigators' discretion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib + Docetaxel
Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of Apatinib in combination with Docetaxel (60 mg/m2)
Time Frame: During the first treatment course, up to 3 weeks
|
During the first treatment course, up to 3 weeks
|
Number of Participants Experienced Dose Limited Toxicity (DLT) in Combination Therapy of Apatinib and Docetaxel
Time Frame: During the first treatment course, up to 3 weeks
|
During the first treatment course, up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 for All Courses
Time Frame: Between the first administration of Docetaxel and 28 days after last administration of Apatinib, up to 1 year
|
Between the first administration of Docetaxel and 28 days after last administration of Apatinib, up to 1 year
|
Objective Response Rate (ORR)
Time Frame: Every 6 weeks from the first treatment course, up to 1 year
|
Every 6 weeks from the first treatment course, up to 1 year
|
Progression-free Survival (PFS)
Time Frame: Every 6 weeks from the first treatment course, up to 2 year
|
Every 6 weeks from the first treatment course, up to 2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Anticipated)
October 1, 2016
Study Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
February 3, 2016
First Submitted That Met QC Criteria
February 22, 2016
First Posted (Estimate)
February 25, 2016
Study Record Updates
Last Update Posted (Estimate)
February 25, 2016
Last Update Submitted That Met QC Criteria
February 22, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenocarcinoma
- Adenocarcinoma of Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Docetaxel
- Apatinib
Other Study ID Numbers
- Ahead-L301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.Active, not recruitingAdenocarcinoma of the LungChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingEGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IVChina
-
Rambam Health Care CampusUnknownLung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
-
Meir Medical CenterUnknownAdenocarcinoma, Bronchiolo-Alveolar | Adenocarcinoma of the LungIsrael
-
Memorial Sloan Kettering Cancer CenterCompletedOligometastatic Lung AdenocarcinomaUnited States
-
Chinese PLA General HospitalUnknown
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Fujian Medical University Union HospitalWu Jieping Medical FoundationActive, not recruitingIA Lung Adenocarcinoma | Combined SegmentectomyChina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Lung AdenocarcinomaUnited States
-
Samsung Medical CenterUnknownLung Adenocarcinoma, Stage IKorea, Republic of
Clinical Trials on Apatinib (250 mg/d) + Docetaxel (60 mg/m2)
-
AstraZenecaCompletedLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUnited States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
-
Memorial Sloan Kettering Cancer CenterBayerRecruitingProstate CancerUnited States, Netherlands, Spain, Brazil
-
Yonsei UniversityCompletedMetastatic Advanced Gastric CancerKorea, Republic of
-
Spanish Oncology Genito-Urinary GroupApices Soluciones S.L.; Janssen, LPCompleted
-
Jina Pharmaceuticals Inc.Lambda Therapeutic Research Ltd.; Intas Pharmaceuticals, Ltd.RecruitingTriple Negative Breast CancerUnited States, India
-
Isofol Medical ABCompleted
-
Prof. Dr. med. Claus RödelActive, not recruitingRectal Cancer Stage IIIGermany
-
Italian Sarcoma GroupFrench Sarcoma Group; Grupo Espanol de Investigacion en SarcomasActive, not recruitingLocalized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in AdultsSpain, Italy
-
Xiayun He, MDCompleted
-
West Japan Thoracic Oncology GroupCompleted